Information about the human genome is rapidly changing the basis for diagnostics and therapies. The lowering costs and availability of genetic data in electronic format will also lower the threshold of clinical exploitation of the data.
The vast amount of medically relevant genetic information will generate a significant challenge for clinicians.
There are wide individual variations in drug response, based on genetic factors. Knowledge about these is available for several essential drugs. For example genetic polymorphism in genes CYP2C19 and CYP2D6 cause variation in metabolic rates of several drugs. In Finland these drugs are prescribed over 550 000 times annually.
The Abomics GeneRx database includes information about genotypes that are associated with clinically relevant variation in drug responsiveness or drug-induced adverse effects. Abomics experts have selected the tests based on scientific evidence.
Database consists of following information:
Database is currently available in English and in Finnish, and will be translated to more languages according to customer needs.
Our database is regularly updated and delivered as XML messages. The messages are unambiguous and well documented. Technical white papers, example data and schema (DTD) definitions are delivered upon request.
Abomics GeneRx can be integrated as a part of electronic health record systems (EHR) drug database. The database update is available as an automated scheduled service.
In the integrated solution, the EHR system alerts immediately in case of clinically significant genetic variation related to the drug prescribed for the patient. Dosing recommendations, available genetic tests and their providers are all available.
Download brochure (PDF)